AcelRx Pharma (NASDAQ: ACRX) reported Q2 EPS of ($0.24), $0.02 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $4.53 million versus the consensus estimate of $2.17 million.

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.